Beginning January 1, 2019, Blue Cross and Blue Shield Federal Employee Program® (FEP) will change the way benefits are applied for the auto-immune infusion drug infliximab (brand names Remicade, Inflectra, and Renflexis). Members who are currently taking the drug may be receiving benefits under either pharmacy or medical.  However, for members who receive their first infusion on or after January 1, 2019, benefits are only available under medical benefits. Members who are receiving benefits under pharmacy prior to January 1, 2019, will continue to receive benefits for the drug under pharmacy.


If you have any questions, please call FEP Customer Service toll free at 800-552-6989.

Featured In:
December 2018 Anthem Provider Newsletter - Virginia